LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

THE IND APPLICATION OF RIVASTIGMINE MULTI-DAY TRANSDERMAL PATCH (LY03013) HAS BEEN ACCEPTED BY CDE IN CHINA

The board of directors (the "Board") of Luye Pharma Group Ltd. (the "Company", together with its subsidiaries "Group") is pleased to announce that the Investigational New Drug ("IND") application of Rivastigmine Multi-Day Transdermal Patch ("Rivastigmine MD", LY03013) developed by the Group for the treatment of Alzheimer's disease has been formally accepted by the Centre for Drug Evaluation ("CDE") of the People's Republic of China ("China").

Rivastigmine MD is the twice-weekly patch formulation of Rivastigmine developed by the Group. It is a key product targeted for the treatment of central nervous system diseases, developed by the research and development ("R&D") platform for transdermal patch of Luye Pharma AG, a subsidiary of the Company in Germany, which is one of the largest independent transdermal drug delivery system manufacturers in Europe. Luye Pharma AG has a highly sophisticated process and high barrier technologies, and has passed US FDA GMP inspections, EU GMP inspections, and Japanese GMP inspections. The rivastigmine once-daily patch has been marketed in more than 20 countries including the United States, Europe, and was approved as the first transdermal patch product according to the requirements of Quality and Efficacy Consistency Evaluation in China. Rivastigmine MD has a lower application frequency than the once-daily rivastigmine patch, enabling it to improve patients' medication adherence, and reducing both caregivers burden and social burden. This product and its formulation methods are protected globally under a number of patents.

The Marketing Authorization Application ("MAA") for Rivastigmine MD has been formally accepted for review by the competent authorities of seven European countries including Germany, the United Kingdom, Spain, Italy, Portugal, Luxembourg and Greece. In addition to Europe and China, the Group also plans to register this product in the United States, Japan and other countries.

Apart from Rivastigmine MD, the Group has a number of other pipeline projects relating to the central nervous system which are under concurrent development in China and overseas markets, with projects such as LY03004 for schizophrenia and bipolar disorder, LY03003 for Parkinson's disease, LY3005 for major depressive disorder, LY03010 for schizophrenia and schizoaffective disorder, LY03012 for chronic pain and LY03014 for postoperative moderate-to-severe acute pain and breakthrough cancer pain. The registration processes of the above pipeline products are progressing well in strategic markets such as China, the U.S., Europe and Japan, and the products are expected to be launched in these countries and further expanded into the global market.

With global trends in population aging, the Board believes that Rivastigmine MD has promising market prospects and will enrich the Group's future product portfolio.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 18 June 2020

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive director of the Company is Mr. SONG Rui Lin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.